Bioavailability and Pharmacokinetic Features of Etoposide in Childhood Acute Lymphoblastic Leukemia Patients

References

• Clark P. I., Slevin M L. The clinical pharmacology of etoposide and teniposide. Clinical Pharmacokinetics 1987; 12: 223–252
   PubMed Web of Science ®Google Scholar
• Henwood J. M., Brogden R N. Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39: 438–490
   PubMed Web of Science ®Google Scholar
• Muggia F. M., Selawry O. S., Hansen H H. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenyli- dene-β-D-glucopyranoside) (NSC-122819). Cancer Chem- other. Rep. 1971; 55: 575–581
   PubMedGoogle Scholar
• Creaven P J. The clinical pharmacology of VM26 and VP-16-213: a brief overview. Cancer Chemother. Pharmacol. 1982; 7: 133–140
   PubMed Web of Science ®Google Scholar
• McLeod H. L., Evans W E. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv. 1993; 17: 253–268
   Google Scholar
• Damayanthi Y., Lown J W. Podophyllotoxins: current status and recent development. Curr. Med. Chem. 1998; 5: 205–252
   PubMed Web of Science ®Google Scholar
• Van Maanen J. M. S., Retel J., de Vries J., Pinedo H M. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer Inst. 1988; 80: 1526–1533
   PubMed Web of Science ®Google Scholar
• Long B. H., Brattain M G. The activity of etoposide (VP16-213) and teniposide (VM-26) against human lung tumor cells in vitro: cytotoxicity and DNA breakage. Etoposide (VP16): current status and new development, B. F. Issell, F. M. Muggia, S K Carter. Academic Press, New York 1984
   Google Scholar
• Minocha A., Long B F. Inhibition of the DNA catenation activity by VP-16-213 and VM-26. Biochem. Biophys. Res. Commun. 1984; 122: 165–170
   PubMed Web of Science ®Google Scholar
• Chen G. L., Yang L., Rowe T. C., Halligan B. D., Tewey K. M., Liu L F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II J. Biol. Chem. 1984; 259: 13560–13566
   Google Scholar
• Haim N., Roman J., Nemec J., Singha B K. Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26). Biochem. Biophys. Res. Commun. 1986; 135: 215–220
   PubMed Web of Science ®Google Scholar
• Sinha B. K., Trash M. A., Kalyanaraman B. Free radical metabolism of VP- 16 and inhibition of anthracycline-induced lipid peroxidation. Biochem. Pharmacol. 1983; 32: 3495–3498
   PubMed Web of Science ®Google Scholar
• Relling M. V., Nemec J., Schuetz E. G., Schuetz J. D., Gonzalez F. J., Korzekwa K R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol. 1994; 45: 352–358
   PubMed Web of Science ®Google Scholar
• Van de Maanen J. M.S., Vries J., Pappie D., van der Akker E., Lafleur M. V. M., Retel J., van der Greef J., Pinedo H M. Cytochrome P450-mediated O-demethylation: a route in the metabolic activation of etoposide. Cancer Res. 1987; 47: 4658–4662
   PubMed Web of Science ®Google Scholar
• Slevin M., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. FM. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 1989; 7: 1333–1340
   PubMed Web of Science ®Google Scholar
• van der Gaast A., Vlastuin M., Kok T. C., Splinter T A. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 ± 100 mg, 2 ± 50 mg, and 4 ± 25 mg of oral etoposide daily for 21 days. Semin. Oncol. 1992; 19(6 Suppl 14): 8–12
   Google Scholar
• Funke I., Wiesneth M., Platow S., Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Ann. Hematol. 2000; 79(3)132–7
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F A. Chronic daily administration of oral etoposide—a phase I trial. J. Clin. Oncol. 1989; 7(3)396–401
   PubMed Web of Science ®Google Scholar
• Davidson A., Lewis I., Pearson A. D., Stevens M. C., Pinkerton C R. 21-day schedule oral etoposide in children-a feasibility study. Eur. J. Cancer 1993; 29A(16)2223–2225
   PubMed Web of Science ®Google Scholar
• Schiavetti A., Varrasso G., Maurizi P., Cappelli C., Clerico A., Properzi E., Castello M A. Ten-day schedule oral etoposide therapy in advanced childhood malignancies. J. Pediatr. Hematol. Oncol. 2000; 22(2)119–124
   PubMed Web of Science ®Google Scholar
• Stewart D. J., Nundy D., Maroun J. A., Tetreault L., Prior J. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat. Rep. 1985; 69: 269–273
   PubMedGoogle Scholar
• Mathew P., Ribeiro R. C., Sonnichsen D., Relling M., Pratt C., Mahmoud H., Bowman L., Meyer W., Avery L., Crist W. Phase I study of oral etoposide in children with refractory solid tumors. J. Clin. Oncol. 1994; 12(7)1452–1457
   PubMed Web of Science ®Google Scholar
• Davidson A., Gowing R., Lowis S., Newell D., Lewis I., Dicks-Mireaux C., Pinkerton C R. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur. J. Cancer 1997; 33(11)1816–1822
   PubMed Web of Science ®Google Scholar
• Needle M. N., Molloy P. T., Geyer J. R., Herman-Liu A., Belasco J. B., Goldwein J. W., Sutton L., Phillips P C. Phase n study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med. Pediatr. Oncol. 1997; 29(1)28–32
   PubMedGoogle Scholar
• Geller R. B., Dix S P. Oral chemotherapy agents in the treatment of leukemia. Drugs, 58 Suppl 1999; 3: 109–118
   Google Scholar
• Chen C. L., Uckun F M. Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma, J. Chromatogr. B. 2000; 744: 91–98
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Onur E. K., Liu X. P., Chen C L. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [(4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline]. Clin. Cancer Res. 1999; 5: 2954–2962
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Bellomy K., O'Neill K., Messinger Johnson Y. T., Chen C L. Pharmacokinetics of TXU(Anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus (HIV)-l. J. Pharmacol. Exp. Ther. 1999; 291: 1301–1307
   PubMed Web of Science ®Google Scholar
• Chen C. L., Uckun F M. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI.-240) with an analytical HPLC method. Pharm. Res. 1999; 16: 1226–1232
   PubMed Web of Science ®Google Scholar
• Chen C. L., Malaviya R., Navara C., Chen H., Bechard B., Mitcheltree G., Liu X. P., Uckun F M. Pharmacokinetics and biological activity of the novel mast cell inhibitor, 4-(3′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm. Res. 1999; 16: 117–122
   PubMed Web of Science ®Google Scholar
• Chen C. L., Levine A., Rao A., O'Neill K., Messinger Y., Myers D. E., Goldman P., Hurvitz C., Casper J. T., Uckun F M. Clinical Pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J. Clin. Pharmacol. 1999; 39(12)1248–1255
   PubMed Web of Science ®Google Scholar
• Gabrielsson J., Weiner D. Phannacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press. 1997
   Google Scholar
• Gibaldi M., Perrier D. Pharmacokinetics. Marcel Dekker, Inc., New York and Basel 1982
   Google Scholar
• Liliemark E., Herngren L., Pettersson B., Peterson C., Liliemark J. Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide. Cancer Lett. 1996; 106: 91–96
   PubMed Web of Science ®Google Scholar
• Greco P. A., Johnson D. H., Hainsworth J D. Chronic oral etoposide. Cancer 1991; 67(1 suppl): 303–309
   Web of Science ®Google Scholar
• Aita P., Robieux I., Sorio R., Tumolo S., Corona G., Cannizzaro R., Colussi A. M., Boiocchi M. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1999; 43(4)287–294
   PubMed Web of Science ®Google Scholar
• Harvey V. J., Slevin M. L., Smythe M. M., Johnston A., Wrigley P. FM. Variable bioavailability following repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol. 1985; 21: 1315–1319
   PubMedGoogle Scholar
• Hande K., Messenger M., Wagner J., Krozely M., Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin. Cancer Res. 1999; 5: 2742–2747
   PubMed Web of Science ®Google Scholar
• Aguilar Ponce J. L., Flores-Picazo Perez Y., Urizar J., Castaneda-Hemandez G., Sierra J. W., Duenas-Gonzalez A., Calderon-Flores E., Segura-Pacheco B. A., Garza-Salazar J. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. Arch. Med. Res. 1999; 30(3)212–215
   PubMed Web of Science ®Google Scholar
• Sinkule J. A., Hutson P., Hayes P. A., Etcubanas E., Evans W E. Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumors. Cancer Res. 1984; 44: 3109–3113
   PubMed Web of Science ®Google Scholar
• Lowis S. P., Pearson A. D., Newell D. R., Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res. 1993; 53: 4881–4889
   Google Scholar
• Sonnichsen D. S., Ribeiro R. C., Luo X., Mathew P., Relling M V. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin. Pharmacol. Ther. 1995; 58: 99–107
   PubMed Web of Science ®Google Scholar
• Evans W. E., Sinkule J. A., Crom W. R., Dow L., Look T., Givera G. Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16-213) in children with cancer. Cancer Chemother. Pharmacol. 1982; 7: 147–150
   PubMed Web of Science ®Google Scholar
• Smyth R. D., Pfeffer M., Scalzo A., Comis R L. Bioavailability and pharmacokinetics of etoposide (VP-16). Seminars in Oncology 1985; 12(Suppl 2): 48–51
   Web of Science ®Google Scholar
• Arbuck S. G., Douglas H. O., Crom W. R., Goodwin P., Silk Y., Cooper C., Evans W E. Etoposide pharmacokinetics in patients with normal and abnormal organ functions. J. Clin. Oncol. 1986; 4: 1690–1695
   PubMed Web of Science ®Google Scholar
• Crom W. R., Glynn-Barnhart A. M., Rodman J. H., Teresi M. E., Kavanagh R. E., Chistianson M. L., Relling M. Y., Evans W E. Pharmacokinetics of anticancer drugs in children. Clin. Pharm. 1987; 12: 168–213
   Google Scholar
• O'Dwyer P. J., Leyland-Jones B., Alonso M. T., Marsoni S., Wittes R E. Etoposide (VP-16-213). Current status of an active anticancer drug. N. Engl. J. Med. 1985; 31: 692–700
   Google Scholar
• Harvey V. J., Slevin M., Joel S. P., Johnston A., Wrigley P. FM. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br. J. Cancer 1985; 52: 363–367
   PubMed Web of Science ®Google Scholar
• Harvey V. J., Slevin M., Joel S. P., Johnston A., Wrigley P. FM. The effect of dose on the bioavailability of oral etoposide. Cancer Chemother. Pharmacol. 1986; 16: 178–181
   PubMed Web of Science ®Google Scholar
• Tillman B., Krumpelmann S., Wurthwein G., Wagner A., Schulze-Westhoff P., Hempel G., Jurgens H., Boos J. Pharmacokinetic aspects of oral administration of etoposide. Klin. Pediatr. 1998; 210: 159–164
   PubMed Web of Science ®Google Scholar
• Relling M. V., Yanishevski Y., Nemec J., Evans W. E., Boyett J. M., Behm F. G., Pui C H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12(3)346–52
   PubMed Web of Science ®Google Scholar
• Stewart C. F., Pieper J. A., Arbuck S. G., Evans W E. Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther. 1989; 45: 49–55
   PubMed Web of Science ®Google Scholar
• Liliemark E. K., Liliemark J., Petterson B., Gruber A., Bjorkholm M., Peterson C. In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia: relation to plasma concentrations and protein binding. Leuk. Lymphoma 1993; 10: 323–328
   PubMed Web of Science ®Google Scholar